Bullish indicating open at $55-$60, IPO prices at $37
Investing.com -- Virbac (EPA:VIRB) SA stock rose 3% after the animal health company reported second-quarter revenue of €363 million, representing growth of 6.4% at constant exchange rates and scope, outpacing the 5.6% growth seen in the first half of 2025.
The company’s first-half growth included approximately 3.5% from price increases and 2.1% from volume growth. The Sasaeah acquisition contributed 2.2% to the overall first-half growth figure.
Virbac’s Companion Animal Products (CAP) segment grew 7.1% at constant exchange rates and scope, driven by strong performance in pet food, dermatology, and specialty products. The Food Producing Animals (FAP) segment increased by 5.1%, supported by positive trends in ruminants, antimicrobials, and nutritional products.
These positive developments were partially offset by an 11% decline in the Chilean aquaculture segment and weakness in the Australian market.
The company confirmed its full-year 2025 guidance, projecting revenue growth of 4-6% at constant exchange rates and scope, with an additional 1% impact from the Sasaeah acquisition. Virbac expects its adjusted EBITA margin to consolidate at the 2024 level of approximately 16% at constant exchange rates and scope.
Additionally, Virbac announced the appointment of Paul Martingell as CEO effective September 1, 2025. Martingell brings over 25 years of international experience, particularly in consumer health, consumer goods, and pharmaceuticals.
The company will release its complete first-half results on September 12.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.